Efficacy of Linaclotide for Patients With Chronic Constipation

Gastroenterology

Volumn 138, Issue 3, 2010, Pages

  Lembo, Anthony J ^a   Kurtz, Caroline B ^b   MacDougall, James E ^b   Lavins, B J ^b   Currie, Mark G ^b   Fitch, Donald A ^b   Jeglinski, Brenda I ^b   Johnston, Jeffrey M ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b IRONWOOD PHARMACEUTICALS INC   (United States)

Author keywords

Guanylin; MD 1100; Secretion; Uroguanylin

Indexed keywords

GUANYLATE CYCLASE INHIBITOR; LINACLOTIDE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; BLOATING; CHRONIC DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FECES ANALYSIS; FECES INCONTINENCE; FEMALE; HUMAN; INTESTINE FUNCTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 77249122338     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.12.050     Document Type: Article

References (27)

1. Stewart W.F., Liberman J.N., Sandler R.S., et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol 94 (1999) 3530-3540
2. Higgins P.D., and Johanson J.F. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 99 (2004) 750-759
3. Lembo A., and Camilleri M. Chronic constipation. N Engl J Med 349 (2003) 1360-1368
4. Pare P., Ferrazzi S., Thompson W.G., et al. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 96 (2001) 3130-3137
5. Wald A., Scarpignato C., Kamm M.A., et al. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther 26 (2007) 227-236
6. Johanson J.F., and Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 25 (2007) 599-608
7. Talley N.J., Lasch K.L., and Baum C.L. A gap in our understanding: chronic constipation and its comorbid conditions. Clin Gastroenterol Hepatol 7 (2009) 9-19
8. Talley N.J. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol Motil 20 Suppl 1 (2008) 121-129
9. Nyrop K.A., Palsson O.S., Levy R.L., et al. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther 26 (2007) 237-248
10. Martin B.C., Barghout V., and Cerulli A. Direct medical costs of constipation in the United States. Manag Care Interface 19 (2006) 43-49
11. Tack J., and Muller-Lissner S. Treatment of chronic constipation: current pharmacologic approaches and future directions. Clin Gastroenterol Hepatol 7 (2009) 502-508 quiz 496
12. Schiller L.R., and Johnson D.A. Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care. Am J Gastroenterol 103 (2008) 815-819
13. Johanson J.F., Morton D., Geenen J., et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 103 (2008) 170-177
14. Johanson J.F., and Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 25 (2007) 1351-1361
15. Forte Jr. L.R. Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol Ther 104 (2004) 137-162
16. Currie M.G., Fok K.F., Kato J., et al. Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci U S A 89 (1992) 947-951
17. Andresen V., Camilleri M., Busciglio I.A., et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133 (2007) 761-768
18. Bueno L., Beaufraud C., Mahajan-Miklos S., et al. Antinocicetive actions of MD-1100, a novel therapeutic agent for C-IBS, in animal models of visceral pain. Am J Gastroenterol 99 Suppl 2 (2004) A283
19. Ustinova E., Bryant A., Reza T., et al. Oral cyclic guanosine monophosphate (cGMP) desensitizes colonic afferents in an animal model of experimental pain. Am J Gastroenterol 103 Suppl 1 (2008) S187
20. Kurtz C.B., Fitch D., Busby R.W., et al. Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmacoldynamics in healthy subjects. Gastroenterology 130 Suppl 2 (2006) A26
21. Johnston J.M., Kurtz C.B., Drossman D.A., et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 104 (2009) 125-132
22. Thompson W.G., Longstreth G.F., Drossman D.A., et al. Functional bowel disorders and functional abdominal pain. Gut 45 Suppl 2 (1999) II43-II47
23. Longstreth G.F., Thompson W.G., Chey W.D., et al. Functional bowel disorders. Gastroenterology 130 (2006) 1480-1491
24. Winawer S., Fletcher R., Rex D., et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 124 (2003) 544-560
25. Lewis S.J., and Heaton K.W. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32 (1997) 920-924
26. Marquis P., De La Loge C., Dubois D., et al. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 40 (2005) 540-551
27. Camilleri M., Kerstens R., Rykx A., et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358 (2008) 2344-2354